Idiopathic Pulmonary Fibrosis Market: By Molecule (nintedanib, Pirfenidone, and Other Drug Types), By Mode of Action (antifibrotic Agents, Tyrosine Kinase Inhibitors, and Other Modes of Action), By End User (hospitals and Clinics, Pharmacies, and Other End Users), and Geography

Idiopathic Pulmonary Fibrosis Market was valued at USD 4,287.3 million in 2023 and is expected to grow at a 7.2% CAGR from 2024 to 2030. Idiopathic Pulmonary Fibrosis is a chronic lung disease characterized by thickening and stiffening of lung tissue, leading to decreased lung function. The increase in global population, especially the growing geriatric population as well as the surge in the population of smokers worldwide contributes to the growth of the idiopathic pulmonary fibrosis market. According to BioNews, Inc., as of October 2021, current smokers are at higher risk of idiopathic pulmonary fibrosis as compared to former smokers. The increasing prevalence of idiopathic pulmonary fibrosis presents a significant opportunity for market growth. As the aging population grows, so does the incidence of idiopathic pulmonary fibrosis. Improved diagnostic testing and awareness campaigns have led to earlier detection and diagnosis.

Moreover, ongoing research and development activities focused on fibrotic diseases, including idiopathic pulmonary fibrosis, offer promising opportunities. Biopharmaceutical companies are investing in novel therapies and treatment options for idiopathic pulmonary fibrosis. However, novel therapeutic interventions for idiopathic pulmonary fibrosis are necessary as approved therapies are limited to slowing the progression of the disease. Secondly, the development of novel therapies for idiopathic pulmonary fibrosis has been hampered by inadequate animal models, the lack of interventions that promote epithelial repair, and the lack of understanding of the contribution of the aging process to damage and fibrosis. Pirfenidone is an orally administered drug with antifibrotic, anti-inflammatory, and antioxidant effects. This drug is used to slow the disease progression in patients with idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis). Unlike other therapies, pirfenidone is an oral medication that provides patients convenience and ease of administration. It has a favorable safety profile and is generally well-tolerated, making it a suitable option for long-term treatment. Innovations in antifibrotic agents, tyrosine kinase inhibitors, and other modes of action provide hope for improved patient outcomes. These advancements contribute to the expansion of the idiopathic pulmonary fibrosis market.

Idiopathic Pulmonary Fibrosis Market Key Developments:

• In January 2023, Daewoong Pharmaceutical signed an agreement with CS Pharmaceuticals for a first-in-class PRS inhibitor Bersiporocin in Greater China. Under this agreement, CSP will in-license bersiporocin for idiopathic pulmonary fibrosis and potentially other fibrotic indications for a total consideration of up to USD 336 million.
• In May 2022, Sandoz launched generic pirfenidone, an AB-rated (fully substitutable) equivalent to Genentech's Esbriet, to treat patients with idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis) in the United States.